C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.530
-0.120 (-4.53%)
At close: Nov 17, 2026, 4:00 PM EST
2.520
-0.010 (-0.40%)
After-hours: Nov 17, 2026, 7:41 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Cemsidomide showed a 53% response rate at 100 mcg in phase I, with two MRD-negative CRs, and is advancing in late-line and elranatamab combination studies. 2027 data are expected to inform a potential late-line NDA and pivotal combination study planned for 2028.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Good morning, everyone. It's still the morning. Day two of our Jefferies Global Healthcare Conference, and it's really been, again, a joy to see everyone, and so grateful for the attendance we see. My name's Akash Tewari. I am Head of our biotech and pharma research efforts within Jefferies, and we have the management team for C4 Therapeutics. I think Andrew's going to start a bit with some prepared remarks, but then we'll get into Q&A. Again, I will just say this, we picked up coverage on this this year, and when I think about established size of a market, and I cover Bristol, when I talk to Bristol, and they will wax poetic about the importance of CELMoDs, and then when I think about SMID-cap companies that are pursuing the same strategy, the list is very short.

I do think that is a very, very unique setup, and I do recommend you talk to them. Andrew, I'll hand it off to you.

Andrew Hirsch
President and CEO, C4 Therapeutics

Great. Thank you, and that's a good introduction. Thanks for having us here. Before I begin, we'll be making forward-looking statements, and this is our disclaimer on that matter. C4 is a targeted protein degradation company, and we're really focused on really exploiting this novel modality. Our key focus right now in the clinic at least is on cemsidomide and multiple myeloma, as well as building a sustainable pipeline. We've got cemsidomide, which is our potential best-in-class cereblon-modulating protein degrader of IKZF1 and three. We are working to establish that as a backbone therapy in multiple myeloma.

In addition, we have a discovery portfolio that is focused on inflammation, neuroinflammation, and neurodegeneration, in validated pathways, but against novel targets where degraders are important, as well as a number of platform collaborations that not only serve to expand the science of TPD, but really help in bringing some non-dilutive capital as part of our strategy. To that end, we are well-capitalized, where our runway is through the end of 2028, which brings us through and beyond some important points. What I'll focus on in my short remarks is cemsidomide. I think that's really where most of the discussion is, given the hybrid method of a presentation and Q&A. I think it's really important to start grounding in the mechanism of IKZF1/3 degradation. What is it, and what does it do?

Way back when Celgene launched the IMIDs, no one actually knew what they did. They were developed in a way that I think was suboptimal in the sense that they are suboptimal by today's degradation standards. What is important about degrading IKZF1 /3 is that it really leads to two outcomes. The first, you can see on the left panel, is it blocks the proliferation of plasma cells, which is really the root cause of multiple myeloma, so it has direct anti-myeloma activity. Importantly, it also activates the immune system, and that is going to be important when we think about the evolving landscape in multiple myeloma. What we know from lenalidomide and pomalidomide is that this mechanism really does serve as a backbone in multiple myeloma. It is used across all lines of treatment in multiple different combinations.

As I mentioned, lenalidomide and pomalidomide are really suboptimal degraders. They are not very potent, and they are frankly not very selective, and that is why you hear a lot about the toxicity profile. The evolving landscape in myeloma is really critical as we think about the future and future development. One important aspect is immune-directed agents moving into earlier lines of treatment, both CAR-Ts and T-cell engagers. We think cemsidomide's profile actually sets it up very nicely to play in the new space, and I will show you why we think that. We ran a phase I first-in-human study, and this is a one-slide summary of the data. What is important is this study was done in the most heavily pre-treated patient population in late-line therapy. You can see that 75% of patients were post-BCMA, but also post-CAR-T and T-cell engager therapy.

That is important because those are patients who, while we think we are curing this disease with these immune-directed agents, there is still an unmet need, they are still showing up, and they have still enrolled in our study. What is really dramatic is our safety profile is differentiated against BMS's next-gen degraders. You can see we have really had well-tolerated profile, and that has been coupled with, we think, really impressive anti-myeloma activity at our recommended phase II dose of 100 mcg. You heard me right, that is micrograms. We had a 53% response rate with two MRD-negative CRs. Just to put that into context, in this late-line, heavily pre-treated population, it is something you do not normally see. Importantly, we saw a robust response at a dose level one below our recommended phase II dose at 75 mcg, and an overall 36% response rate.

We think that this is what really shows it is a best- in- class. It really has class-leading efficacy, anti-myeloma activity, with a sort of, we think, best-in-class safety profile. Combined together, that positions it well. I mentioned the second MOA, and this slide illustrates that. You can see across all doses, and what we are showing here is representative of the wealth of data we have on immune cell activation. The first two left panels are demonstrating our ability to activate T cells, and the consequence of that, you see increased IL-2 cytokine production across really all the dose levels that we studied, which is critically important as we think about combination strategies in the future. That leads to where the market opportunity is, and we think there is really two important opportunities.

The first is, as these immune-directed agents move into earlier lines of treatment, patients are living longer, and that's great for patients, but these are not cures, despite what others in the field may start to talk about. We think what's happening there is two things. That's going to increase the population in the later line, fourth line plus, as those patients ultimately progress, and there is a need for an all-oral therapy for these patients. In addition, as we think about these agents moving into earlier lines of treatment, we think there's an opportunity to boost their activity and improve their duration by combining with an IKZF1/3 degrader. That's really where our development strategy is focused. Currently, we have two ongoing studies.

The first is a phase II single-arm study we call MOMENTUM in late-line patients, and that is positioned as a potential for an accelerated approval. We're also running a phase Ib combination study with a BiTE, Pfizer's elranatamab, and that's in conjunction with a supply agreement with Pfizer. That study is going to support a pivotal study with the same combination, where we have another shot at accelerated approval with an MRD-negative CR. Importantly, we have a time-to-event endpoint that will serve as the confirmatory endpoint for both the accelerated approval in this second-line setting, but also for the late-line setting in the MOMENTUM study. Lastly, we're running a combination study with daratumumab and with carfilzomib as a way to establish broad combinability across the class, because as I mentioned, I think the profile that we demonstrated suggests that.

Next year is setting up to be a really critical year. This year was one of execution, where we are aggressively enrolling our studies and generating data. Next year is really going to be data-rich. We expect to complete enrollment in the first quarter in the MOMENTUM study, with an initial response rate data readout in the second half. In the middle of the year, we expect to share data from all doses and cohorts studied in the elranatamab combination study in the middle of 2027, as well as start that combination study with a CD38 and a proteasome inhibitor. That's going to be pivotal in terms of setting up 2028, where, with the data supportive, we expect to submit by the end of the year for an NDA in that late-line setting and initiate that pivotal phase III study in combination.

Drilling into the details here, MOMENTUM's a 100-patient study using the 100 mcg recommended phase II dose on a 14-day on, 14-day off schedule, and the primary endpoint is response rate. That trial is well underway, and we are confident that we're going to complete enrollment in the first quarter of next year. The phase Ib study, we started that earlier this year, and we've progressed that nicely. We started off one dose level below the recommended phase II dose at 75 mcg. That has been declared safe, and we've now both escalated to 100 mcg, the recommended phase II dose, as well as expanded to get additional patient experience at 75 mcg.

I think what is notable about that is when you look at other drugs in the class, when they have tried to do similar combinations, they have had to de-escalate from their recommended phase II dose, almost two to three doses below that. In contrast, we have been able to establish safety at one dose level below, and now working to establish safety at our recommended phase II dose. I think that speaks to the safety profile and its broad potential for combinability, really across the multiple myeloma landscape. I will end my prepared remarks just reinforcing IKZF1/3 degradation is really, it is a foundational mechanism in treating myeloma across all different lines and multiple combinations. The profile we have established suggests that it is a best- in- class in terms of both the combination of safety and efficacy.

We are pursuing two distinct meaningful opportunities, both in the late line and in the second line or later. We have a strategic development plan that is set up to capture those opportunities with a data-rich 2027. With that, we will open it up to questions. Thank you.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Really appreciate the prepared remarks. I want to actually start off with, obviously, you have two important readouts. You have the Pfizer bispecific, and then you get some of your fourth-line data next year. We also get some really critical data sets from Bristol, SUCCESSOR-1, and then we also get some LBCL data. But the idea that this is going to move beyond just multiple myeloma. This is more conceptual. What do you feel like investors do not understand about the CELMoD opportunity that is just blaringly obvious for your team right now? How do you think the Bristol readouts, and not just your own, change that narrative? How soon are people going to realize, like, this is happening sooner than we think?

Andrew Hirsch
President and CEO, C4 Therapeutics

I will answer first, and then I will have Len comment. I think what is challenging is no one is really focused on this mechanism, right? It is an old mechanism that was really, as I mentioned, when Celgene launched lenalidomide and pomalidomide, nobody actually knew how they worked. Nobody knew they were degraders. They called them IMiDs, immunomodulatory drugs. But they did not actually know how they worked. No one has really paid attention to the mechanism and how important it is. I think that is an important piece, because what everyone is excited about, the shiny new toys of CAR-T and T-cell engagers, and do not get me wrong, they are phenomenal drugs, and they have led to meaningful improvements in patient outcomes. But this is, as I mentioned, a critical mechanism for the disease, and I think people lose sight of that.

And that's why maybe they don't understand, and they're not clear that, are these optimized degraders better than lenalidomide and pomalidomide? Certainly, when we look at the data and we looked at the safety profile, we looked at the selectivity and the potency, we believe they are, and that's got to translate into the clinic.

Len Reyno
Chief Medical Officer, C4 Therapeutics

I'm Len, I'm the Chief Medical Officer. Obviously, I agree with that. I would drill down a little bit on some of the concepts. I think if you think about the space, and Bristol, obviously, leadership with IMiDs, but they were developed pretty much as assets. They worked, they were given in combination. There was not a lot of thought of the mechanism of action because people didn't know what it was. At the same time that doing that, the space is overwhelmed with exciting new drugs with novel mechanism of actions. They put CELMoDs in clinic, and they put them in an asset replacement strategy.

To try to replace and maintain their franchise in first and second line. A laudable strategy. I probably would have done the same thing. While they're doing that, though, the excitement in the space has been on novel mechanism of action, and in fact, has been on recently, revisiting potent degraders and what they're actually doing. What we've been able to take advantage of, and I don't think people have fully processed it, to get back to your original very excellent question, is we've been able to say, "Hey, okay, Bristol has those plans. They're well-developed. Assume they're going to get multiple positive studies. They're going to get labels." They got their first one this summer. What can we do that actually is different and maximizes the unique features of cemsidomide?

What Andrew just outlined for you was that we have two clinical trials that between the two of them could lead to full approval in accomplishing from second line to late line, and that second line approval, which is clearly most valuable, not married to yesterday's drugs, but married to today's drugs. In terms of the differentiation that we have, we have the data that you just saw, but there's emerging data that actually helps sort of put a spotlight on it. Andrew pointed out correctly that we've cleared 75 mcg in our first dose with BiTE. That's exciting. That was extremely exciting to me.

because that 75 mcg dose level has a 40% response rate. Why does it matter? Because over and above any enhancement of the immune effect, if you can introduce a drug early in BiTE therapy that has its own 40% response rate, the chance that you can actually drive deeper, more meaningful MRD-negative CRs with that combination, I think, can be inferred as a hypothesis that's strongly supported. The other piece of emerging data that's really helpful in distinguishing, I think, is what Andrew alluded to and showed you the data, that we have immune enhancement at all our clinically relevant doses. We couldn't distinguish a difference between those dose levels. At ASH coming up, you'll see some mezigdomide data with a BiTE from Bristol, and they're interrogating 0.3 and 0.6.

But one of the things that's in the abstract that's provocative to us, because it's different, is they point out that they don't get the immune enhancement at 0.3 and only get it at 0.6. Why does it matter? Again, in terms of broad-based strategies where you put a drug in phase III and expect that drug to be successful, the general rule in oncology that I think is held well and true is if you have a drug that has a broad mechanistic rationale over a range of doses with an effective safety profile, that drug's going to be a winner. So, I think there is room for both companies, but our differentiated strategy, I think, sets us up well.

And our differentiated strategy, to be really clear, is rooted in the primary molecular characteristics of the molecule and supported by really compelling data in every trial that we've done to date.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Okay. Very helpful. And I want to hit on this more because, again, I think once people understand the concept, then you can really apply to so many different phases of multiple myeloma and actually, frankly, beyond. So, let's put a finer point on this. You've got MOMENTUM reading out mid-next year. This is the combo with the Pfizer BCMA. You guys have shown, and we've seen with Bristol, yeah, you can get an 80%, 90% response rate. But that doesn't seem like what you're telling me to focus on. It's duration on treatment and deepening response.

Len Reyno
Chief Medical Officer, C4 Therapeutics

Right.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

And so, help us understand. I think because everyone expects the high response rate.

Len Reyno
Chief Medical Officer, C4 Therapeutics

Yeah.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

What do you think the duration on treatment, the duration of response could rival? Could we see that BCMA with the CELMoD off the shelf, we have depth and duration of response that would rival any of the CAR-T regimens?

Len Reyno
Chief Medical Officer, C4 Therapeutics

I think that is absolutely the goal, and I think that is well-supported by our own dataset. To your point, all of these combinations are going to have very high response rates. They are going to approach 100%. You are going to be interested even then in differentiating on what proportion are CRs, what proportion are MRD-negative CRs. But cautionary note, they are all going to be initially small datasets that are not powered for really true comparisons, but you are going to want to see more of that. I think that the promise that is well-supported by the data is that you can get to a place where when a clinician is seeing a patient in a future state, not that far off from now-

that, yes, there will be a choice to be made, and CAR-Ts currently have a lead, if you will, in the sense that people believe that all other things being equal, if you can give a CAR-T, you probably will get the highest response rate. There are some caveats there, though, that people are missing. The caveat there is, if you look at the data in terms of the number of patients who are referred to a CAR-T center who actually get the CAR-T, when they talk about the high response rate of CAR-T, it is in the patients who actually get it.

You have lost some patients in the actual. They were referred for CAR-T, they never get CAR-T. I think there is going to be a really compelling conversation space to talk with patients about, is CAR-T really better for you, and then the value added with the, so a BiTE combination with a drug like cemsidomide. As we develop further, I think we will have a better handle on what the delta is on long-term PFS, and I think speculating on how big that might be would be premature. But I would anticipate it will be real, and will fit with an emerging practice pattern where a BiTE plus a drug like cemsidomide with, I should not say like, with cemsidomide

will be the best choice.

Andrew Hirsch
President and CEO, C4 Therapeutics

I think that is, I will just add, that is important because when you think about where myeloma is treated, 70%-80% is treated in the community.

They are not doing CAR-T in the community. Our latest data suggests that about 25% of patients who are eligible for CAR-T are actually getting it. There is a real unmet need for deep, durable responses that can be administered in the community, and that is where we think a TCE plus cemsidomide is really going to shine.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Right. Just so that, let us call our shot here. How do you define, when you are looking at the BCMA data sets that are coming up and the indication and setting that you are testing, what is the investor bar for CAR-T durability of response, CR, response rate as a whole, that we should at least be thinking about? Let us say that you are even in that ballpark. It sounds like that is how you would define that as a significant one. What are the bars that you are seeing?

Len Reyno
Chief Medical Officer, C4 Therapeutics

The bars are moving constantly.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

I know.

Len Reyno
Chief Medical Officer, C4 Therapeutics

As we get more data.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

I bet.

Len Reyno
Chief Medical Officer, C4 Therapeutics

That would be the first thing. I think the second part of that, though, the response rate is going to need to be close to 100%. I think what's emerging in the literature right now on various trial modalities is that there is a baseline expectation in second line that your MRD-negative CR rate should be in the order of between 40% and 50%.

I think that's an important benchmark for planning, because in terms of planning a phase III trial, which is really in some respects the more important aspect of your question-

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Yeah

Len Reyno
Chief Medical Officer, C4 Therapeutics

-in terms of near-term investment, how do you plan a phase III trial that is the most cost-effective phase III trial, you're not overspending on it, that gets you to where you need to go as fast as possible? We're doing that work right now, and the benchmarks we're looking at is, again, an MRD-negative rate of between 40% and 50%. Because you don't have true proof of concept data in terms of the size, you have to pick a benchmark. You're going to have to get at least 15% or 20% higher than that.

That will map in future to due course to a PFS benefit, but it's hard to know what that will be right now in the current environment. What I can tell you from a regulatory perspective, at least from a U.S. perspective, your MRD-negative CR rate will be compared within your trial. Okay? You have to beat your standard arm. Likewise, your PFS benchmark will be within your trial.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Right.

Len Reyno
Chief Medical Officer, C4 Therapeutics

Then you'll get into the usual situation, which you'll see, getting to ASH and post-ASH, where everybody's doing cross-trial comparisons and they're useful to a point, but at some point they don't really help you get where you need to go.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Understand. Last point on this, and I respect that. I agree. I think it is 40%-50%. That's a high bar, but it does seem like your team's not walking away from that. Duration on treatment, because that's where I feel like people miss on the BCMAs. They're not on the drug for a particularly long period of time. The infections start to increase over time.

Len Reyno
Chief Medical Officer, C4 Therapeutics

Well, let's-

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Yeah.

Len Reyno
Chief Medical Officer, C4 Therapeutics

Yeah, so let's talk about-

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

But just to put a finer point on that. Do you feel like in combination with the CELMoD, you would have a material improvement on the duration of response compared to just BCMA's by themselves? And how would you define that material improvement?

Len Reyno
Chief Medical Officer, C4 Therapeutics

It would be getting way over my skis to try to-

Andrew Hirsch
President and CEO, C4 Therapeutics

Yeah

Len Reyno
Chief Medical Officer, C4 Therapeutics

-define the material improvement. Do I think it's a reasonable hypothesis we can improve it? Yes, and here's why. We know that the labels for BiTEs currently say that, give them now and forever unless you're limited by toxicity or progression.

We also know that thought leaders don't do that. That thought leaders, and not even thought leaders, clinicians don't do that. That after a period of time, and if you did a survey, we just had an ad board with 11 top thought leaders, there was no consensus when they did it. But after at least a year, maybe two years, people are stopping the BiTE. I think from a theoretical point of view, there'd be less incentive to stop the cemsidomide-

-because it's easier to give. To your point about infection risk, I think that's obviously a really important one. It appears to me, my understanding of the data, that the BiTE infection risk, it's not so much it goes up over time, it just doesn't go down.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Yeah.

Len Reyno
Chief Medical Officer, C4 Therapeutics

It's a static long-term infective risk, which people are much, much better at managing that risk now than they were even two years ago. But it's still an issue. What we showed in our cemsidomide data, now we'll get data with BiTE, but what's really provocative in our cemsidomide data is our risk of safety did not go up over time. That in fact the predicted changes in neutrophil counts, et cetera, early on in cemsidomide were likely associated with the disease being out of control, and that long term, we don't have patients coming off cemsidomide for safety-related reasons. So, I think there's a lot embedded at your very good question, but getting too far out over it, I think, would be-

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

But it almost sounds like to me it's induction and then cemsidomide maintenance-

Andrew Hirsch
President and CEO, C4 Therapeutics

Yeah

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

-is really what you're going for.

Len Reyno
Chief Medical Officer, C4 Therapeutics

Well, yeah, we'll have to be separate because we think that will happen organically with data, but we first need to get the drug approved.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Right.

Len Reyno
Chief Medical Officer, C4 Therapeutics

And likewise, that protocol will be specific, written with approval in mind.

Andrew Hirsch
President and CEO, C4 Therapeutics

Yeah, that's not the study we're doing, but you're right. As we hear KOLs talk more about fixed duration with the BiTE-

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Yeah

Andrew Hirsch
President and CEO, C4 Therapeutics

-which is driving people into deep MRD-negative CRs with a combination. Then, as Len said, at the right time, there is no consensus removing the BiTE. But as we've shown, cemsidomide is very well tolerated and very effective, and you can imagine a world where you're on a cemsidomide maintenance therapy to maintain that deep response.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

I'm going to stick in a cheeky question at the end. It reminds me, we had Madrigal yesterday, and again, people, NASH is not a market. Oh, it looks like it's a market. Then the floodgates kind of open. I can't help but think with CELMoDs, it's this same dynamic where it's like, look, the first thing I hear when I talk to you guys, they're like, "Celgene was talking about this. Give me a break." It takes a long time. It takes a lot of capital investment. It's hard to do as a mid-cap company. I can't help but think 2027, you get SUCCESSOR-1, you get the head-to-head study against Len in maintenance, and we get proof of concepts with both of your programs too, and with a potential pivotal path.

Do you think by the time we're having this discussion next year, Bristol's excited, you're excited. Do you feel like from a strategic perspective, once we get some of those unlocks, the amount of pharma companies that would be interested in this target will materially increase? What's been the gating factor so far?

Andrew Hirsch
President and CEO, C4 Therapeutics

It's hard to predict, and I'm not going to sort of guess. Look, I do think this is a best-in-class asset with a critical modality in multiple myeloma and should be part of your portfolio. That said, our focus is on maximizing the value of cemsidomide and executing the development plan that we've laid out, that I just articulated. That's really where we're focused. If someone in someone's boardroom decides to do something, that's beyond my control, and obviously, we will do the right thing for shareholders. But at this point, our focus is on executing the plan that I've outlined.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

I understand. Last question. I know we're over, but last question. The late-line pivotal data, fourth line plus with Dex, there's been turnover with the agency, and also what happened with DOGE, you had some of the division heads leave. What I've noticed is it doesn't mean that the bar gets It's not like everything got easier or everything got worse. It really then reverts back to who's approving your drug and what biases maybe individuals within each review division have. So it's not a broad-based take. How confident are you with your team that you will have a path to pivotal in the fourth-line setting? What is that bar that's been communicated with you by the FDA?

Andrew Hirsch
President and CEO, C4 Therapeutics

Yes. I think it's important to put in context how the FDA views single-arm studies for potential for accelerated approval, right? They will always tell you, "We prefer a randomized study, but we recognize there are certain scenarios where that's not possible." They will certainly look at it, but they won't give you that determination until you show up with data and have that discussion. So it's premature to sort of say where we are. But the other important component is it's going to be judged in the context of the then current standard of care in that setting-

-when we show up for the data. So it really depends on that, and then to your point, on who's there and who we're speaking to.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Has that changed at all, or it is the same team?

Andrew Hirsch
President and CEO, C4 Therapeutics

No, it has changed.

Len Reyno
Chief Medical Officer, C4 Therapeutics

It has changed.

Andrew Hirsch
President and CEO, C4 Therapeutics

It has changed. The division director that we have been speaking with left, and there is a transition.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Okay. Okay, we got to go.